British pharmaceuticals giant AstraZeneca on Friday reported $275 million (227 million euros) in sales from its Covid vaccine in the first three months of the year.
It’s the first time the company has released sales figures for one of the world’s most popular vaccines.
The Covid-19 vaccine, developed by AstraZeneca in collaboration with the University of Oxford, has been critical in Britain’s rapid vaccination campaign. It is being sold at a loss by the company.
However, public trust in the vaccine has been shaken by concerns about links to extremely rare blood clots, and the company is fighting the EU over delivery delays.
The company revealed the information in an earnings statement that showed net profit more than doubled in the first quarter to $1.56 billion, up from $780 million a year ago.
In the reporting period, revenue increased 15% to $7.32 billion, or 11% at constant exchange rates.
Revenues increased by 11% — or 7.0 percent at constant rates — to $7.045 billion, excluding the contribution from the Covid jab.
Strong sales of new cancer drugs boosted AstraZeneca’s quarterly performance, the company said on Thursday.